​

Intra-Cellular Therapies (ITCI) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ITCI Stock Forecast

Intra-Cellular Therapies (ITCI) stock forecast, based on 23 Wall Street analysts, predicts a 12-month average price target of $105.50, with a high of $132.00 and a low of $79.00. This represents a -20.00% decline from the last price of $131.87.

$65 $79 $93 $107 $121 $135 High: $132 Avg: $105.5 Low: $79 Last Closed Price: $131.87

ITCI Stock Rating

Intra-Cellular Therapies stock's rating consensus is Buy, based on 23 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 14 Buy (60.87%), 9 Hold (39.13%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 23 0 9 14 Strong Sell Sell Hold Buy Strong Buy

ITCI Price Target Upside V Benchmarks

TypeNameUpside
StockIntra-Cellular Therapies-20.00%
SectorHealthcare Stocks 33.91%
IndustrySpecialty & Generic Drug Manufacturers Stocks46.81%

Price Target Trends

1M3M12M
# Anlaysts--13
Avg Price Target--$98.46
Last Closing Price$131.87$131.87$131.87
Upside/Downside---25.34%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25129--12
Mar, 251210--13
Feb, 25139--13
Jan, 25598--22
Dec, 24592--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Jan 14, 2025David AmsellemPiper Sandler$132.00$83.2358.60%0.10%
Oct 30, 2024Corinne JenkinsGoldman Sachs$79.00$85.47-7.57%-40.09%
Sep 05, 2024David AmsellemPiper Sandler$92.00$72.4227.04%-30.23%
Aug 08, 2024Brian AbrahamsRBC Capital$106.00$73.6343.96%-19.62%
Aug 07, 2024Corinne JenkinsGoldman Sachs$74.00$73.630.50%-43.88%
Jul 22, 2024Ami FadiaNeedham$100.00$74.8633.58%-24.17%
Jun 25, 2024Ashwani VermaUBS$83.00$72.4214.61%-37.06%
Jun 20, 2024Graig SuvannavejhMizuho Securities$100.00$76.0631.48%-24.17%
Jun 18, 2024Brian AbrahamsRBC Capital$103.00$75.4836.46%-21.89%
May 07, 2024Brian AbrahamsRBC Capital$96.00$71.2134.81%-27.20%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Jan 14, 2025Piper SandlerOverweightNeutraldowngrade
Oct 31, 2024Cantor FitzgeraldOverweightOverweighthold
Oct 30, 2024Goldman SachsNeutralNeutralhold
Oct 11, 2024Morgan StanleyOverweightOverweighthold
Oct 04, 2024UBSBuyBuyhold
Sep 06, 2024RBC CapitalUnderperformUnderperformhold
Sep 05, 2024Piper SandlerOverweightupgrade
Aug 08, 2024RBC CapitalOutperformOutperformhold
Aug 07, 2024Goldman SachsNeutralNeutralhold
Jul 22, 2024RBC CapitalUnderperformUnderperformhold

Financial Forecast

EPS Forecast

$-5 $-1 $3 $7 $11 $15 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.23$-3.50$-2.72$-1.46$-0.72----
Avg Forecast$-3.33$-3.45$-2.87$-1.62$-0.62$0.37$3.72$7.24$10.73
High Forecast$-3.02$-3.13$-2.68$-1.52$-0.34$2.03$7.19$12.16$11.93
Low Forecast$-3.70$-3.84$-3.10$-1.73$-0.88$-1.73$0.89$2.53$9.89
Surprise %-3.00%1.45%-5.23%-9.88%16.13%----

Revenue Forecast

$0 $600M $1B $2B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$22.53M$81.71M$249.13M$464.37M$680.85M----
Avg Forecast$22.19M$83.14M$249.37M$468.13M$675.74M$934.75M$1.43B$2.01B$2.62B
High Forecast$24.09M$90.24M$264.36M$471.66M$676.50M$1.01B$1.44B$2.04B$2.85B
Low Forecast$20.60M$77.16M$236.16M$462.67M$674.88M$895.45M$1.42B$1.97B$2.46B
Surprise %1.53%-1.73%-0.10%-0.80%0.76%----

Net Income Forecast

$-500M $-100M $300M $700M $1B $2B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-227.01M$-284.13M$-256.26M$-139.67M$-74.68M----
Avg Forecast$-251.72M$-331.16M$-327.11M$-139.67M$-58.71M$30.42M$389.10M$792.00M$1.03B
High Forecast$-201.37M$-300.21M$-261.69M$-111.74M$-32.62M$194.57M$688.93M$1.17B$1.14B
Low Forecast$-302.06M$-367.94M$-392.53M$-167.61M$-84.80M$-166.26M$85.62M$242.24M$948.28M
Surprise %-9.82%-14.20%-21.66%-27.20%----

ITCI Forecast FAQ

Is Intra-Cellular Therapies stock a buy?

Intra-Cellular Therapies stock has a consensus rating of Buy, based on 23 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 14 Buy, 9 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Intra-Cellular Therapies is a favorable investment for most analysts.

What is Intra-Cellular Therapies's price target?

Intra-Cellular Therapies's price target, set by 23 Wall Street analysts, averages $105.5 over the next 12 months. The price target range spans from $79 at the low end to $132 at the high end, suggesting a potential -20.00% change from the previous closing price of $131.87.

How does Intra-Cellular Therapies stock forecast compare to its benchmarks?

Intra-Cellular Therapies's stock forecast shows a -20.00% downside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the specialty & generic drug manufacturers stocks industry (46.81%).

What is the breakdown of analyst ratings for Intra-Cellular Therapies over the past three months?

  • April 2025: 8.33% Strong Buy, 16.67% Buy, 75.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 7.69% Strong Buy, 15.38% Buy, 76.92% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 7.69% Strong Buy, 23.08% Buy, 69.23% Hold, 0% Sell, 0% Strong Sell.

What is Intra-Cellular Therapies’s EPS forecast?

Intra-Cellular Therapies's average annual EPS forecast for its fiscal year ending in December 2025 is $0.37, marking a -151.39% decrease from the reported $-0.72 in 2024. Estimates for the following years are $3.72 in 2026, $7.24 in 2027, and $10.73 in 2028.

What is Intra-Cellular Therapies’s revenue forecast?

Intra-Cellular Therapies's average annual revenue forecast for its fiscal year ending in December 2025 is $934.75M, reflecting a 37.29% increase from the reported $680.85M in 2024. The forecast for 2026 is $1.43B, followed by $2.01B for 2027, and $2.62B for 2028.

What is Intra-Cellular Therapies’s net income forecast?

Intra-Cellular Therapies's net income forecast for the fiscal year ending in December 2025 stands at $30.42M, representing a -140.74% decrease from the reported $-74.676M in 2024. Projections indicate $389.1M in 2026, $792M in 2027, and $1.03B in 2028.